Baird analyst Jeff Johnson raised the firm’s price target on Zimmer Biomet to $145 from $133 and keeps an Outperform rating on the shares. The analyst said 4Q revenue/earnings exceeded us/Street. Guidance for 2023 was also above our model/consensus, and with management pointing to strong January trends, our math suggesting Fx guidance likely embeds conservatism.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZBH:
- Zimmer Biomet price target raised to $135 from $130 at Piper Sandler
- Zimmer Biomet sees FY23 adjusted EPS $6.95-$7.15, consensus $6.98
- Zimmer Biomet reports Q4 EPS $1.88, consensus $1.83
- Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results
- Increasing Medical Issues Bode Well for Zimmer Biomet Stock (NYSE:ZBH)